Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1999-6-16
pubmed:abstractText
In this cross-sectional survey conducted at the end of 1997 among the physicians of participants of the Swiss HIV Cohort Study (SHCS), 1487 of 2154 patients (69.0%) were treated with highly active antiretroviral treatment (HAART) defined as triple therapy with a combination of one or two reverse transcriptase inhibitors, and one or two protease inhibitors; 541 patients (25.1%) had never received such treatment. The physician's perception that the patient would not comply with treatment was one reason for not prescribing HAART to 20% of these patients (110). Physicians indicated that the most common reasons for the patient to refuse HAART were the fear of side effects (18%) and the patient's perception that treatment was too complicated (18%). Among 126 patients (5.8%) no longer receiving HAART, the most common reasons for discontinuing treatment were actual side effects (61%) or the fear of side effects (25%). Overall, 16% of patients did not receive therapy in accord with official Swiss guidelines. Multivariate logistic regression analysis indicated that patients with lower education, active intravenous drug users outside of a drug substitution program, and those who acquired HIV infection through intravenous drug use had a significantly higher risk of inadequate treatment. The physician's judgment of patient adherence and the physician's perception of the patient's fear of side effects are critical for the prescription of HAART. Physicians should address these issues to prevent unilateral withholding of treatment and increase the proportion of patients who may benefit from current antiretroviral therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1525-4135
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
114-9
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:10360802-Anti-HIV Agents, pubmed-meshheading:10360802-CD4 Lymphocyte Count, pubmed-meshheading:10360802-Cohort Studies, pubmed-meshheading:10360802-Cross-Sectional Studies, pubmed-meshheading:10360802-Drug Prescriptions, pubmed-meshheading:10360802-Drug Therapy, Combination, pubmed-meshheading:10360802-Drug Utilization, pubmed-meshheading:10360802-Education, pubmed-meshheading:10360802-Female, pubmed-meshheading:10360802-Guideline Adherence, pubmed-meshheading:10360802-HIV Infections, pubmed-meshheading:10360802-HIV Protease Inhibitors, pubmed-meshheading:10360802-Humans, pubmed-meshheading:10360802-Male, pubmed-meshheading:10360802-Patient Compliance, pubmed-meshheading:10360802-Physician's Practice Patterns, pubmed-meshheading:10360802-Reverse Transcriptase Inhibitors, pubmed-meshheading:10360802-Risk Factors, pubmed-meshheading:10360802-Substance Abuse, Intravenous, pubmed-meshheading:10360802-Switzerland, pubmed-meshheading:10360802-Treatment Refusal
pubmed:year
1999
pubmed:articleTitle
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.
pubmed:affiliation
Outpatient Department of Internal Medicine, University Hospital, Basel, Switzerland.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't